Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. Such Compositions comprise inter alia an anti-CTLA-4 agent, e.g. ipilimumab or tremelimumab in combination with other chemotherapeutic agents such as dasatinib, imatinib, paclitaxel, gemcitabine, cisplatin or etoposide.
